ROG - IPO Update: ADC Therapeutics Readies $200 Million IPO
Quick Take
ADC Therapeutics (ADCT) intends to raise $200 million in an IPO of its common shares, per an F-1/A registration statement.
The company is developing a pipeline of drug treatment candidates for various blood cancers and solid tumors.
ADCT has shown promising trial results and has the growing backing of AstraZeneca, although the IPO's proposed valuation is quite high.
Company & Technology
Epalinges, Switzerland-based ADC was founded in 2011 as a Spirogen (LON:AZN) spin-off to develop ADC-based therapeutics for patients suffering from hematological malignancies and solid tumors.
Management is